2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee ( IEC) guidelines. 3. Histologically -confirmed pancreatic cancer with progression on or after SoC therapy. 4. ECOG performance status of 0 to 2. 5. Have at least 1 measurable lesion of ≥ 1.5 cm. 6. Must have a recent formalin -fixed, paraffin-embedded (FFPE) tumor biopsy specimen following the conclusion of the most recent anti- cancer treatment and be willing to release the specimen for tumor molecular profiling analysis. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period. 7. Must be willing to provide blood samples for exploratory analyses. 8. Ability to attend required study visits and return for adequate follow-up, as required by this protocol. 9. Agreement to practice effective contraception for female subjects with child -bearing potential and non- sterile males. Female subjects of chi ld-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Exclusion Criteria: 1. History of persistent grade 2 or h igher (CTCAE Version 4.03) hematological toxicity resulting from previous therapy. 2. History of other active malignancies or brain metastasis except: controlled basal cell carcinoma; prior history of in situ cancer (eg, breast, melanoma, cervical); prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy) and with undetectable prostate -specific antigen ( PSA) (< 0.2 ng/mL); bulky (≥ 1.5 cm) disease with metastasis in the central hilar area of the chest and involving the pulmonary vasculature. Subjects with a history of another malignancy must have > 5 years without evidence of disease. Confidential and Proprietary 9 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Amendment 2 3. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications. 4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma). 5. History of organ transplant requiring imm unosuppression. 6. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis). 7. Requires whole blood transfusion to meet eligibility criteria. 8. Inadequate organ function, evidenced by the following laboratory results: a. White bl ood cell (WBC) count < 3,500 cells/mm3 b. Absolute neutrophil count < 1,500 cells/mm3. c. Platelet count < 100,000 cells/mm3. d. Hemoglobin < 9 g/dL. e. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert’s syndrome) . f. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases). g. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases). h. Serum creatinine > 2.0 mg/dL or 177 μmol/L. i. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) >1.5 × ULN (unless on therapeutic anti-coagulation). 9. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; conge stive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. 10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. 11. Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). 12. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednis olone), excluding inhaled steroids. Short- term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. 13. Known hypersensitivity to any component of the study medication(s). 14. Subjects takin g any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. See Excluded Medications list. Confidential and Proprietary 10 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Amendment 2 15. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer. 16.